We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Formaldehyde Substitute Fixatives Appraised for Histology

By LabMedica International staff writers
Posted on 28 Sep 2011
In histology and pathology laboratories, neutral buffered formalin (NBF) has been the gold standard fixative for decades, but formaldehyde is known to be toxic. More...


Other less toxic alcohol-based cross-linking or non–cross-linking fixatives have advantages that include faster fixation; elimination of carcinogenic vapors; better preservation of glycogen, DNA, and RNA; greater staining avidity; and no need for enzyme predigestion for immunohistochemical analysis.

Scientists at the University Medical Center Utrecht (the Netherlands) tested three cross-linking and non–cross-linking alcohol-based fixatives for routine staining in comparison with NBF, an aqueous solution of 4% buffered formaldehyde. The aim was to observe the fixation on tissue morphologic features and the quality of special histological stains and immunohistochemical stains in comparison with NBF.

Fresh tissue samples from many different organs were divided into four equal pieces and fixed in all fixatives for varying times. After paraffin embedding, staining with hematoxylin and eosin (H&E), seven common histochemical stains, and nine common immunohistochemical stains were performed. Fixation with the non-linking RCL2 (Alphelys; Plaisir, France) resulted in soft and slippery tissue, causing sectioning difficulties. The cross-linking the aldehyde-containing F-Solv (Adamas; Rhenen, The Netherlands) and the non–cross-linking FineFIX (Milestone; Bergamo, Italy) led to partial tissue disintegration during fixation.

F-Solv performed morphologically similar to NBF but needed considerable protocol adjustments before being applicable in daily histology and immunohistochemical practice. FineFIX did not necessitate major protocol changes but caused shrinkage artifacts, degranulation, and lysis of red blood cells (RBC). RCL2 generated morphologically overall good results without major protocol changes, but caused pigment deposition, degranulation, and erythrocytic lysis. The alcohol-based fixatives had positive and negative attributes and environmental drawbacks, and none was overall comparable to NBF with regard to macroscopy, morphologic evaluation, and immunohistochemical studies.

The authors concluded that before replacing formalin with another fixative in a surgical pathology laboratory, all levels of pathology must be examined thoroughly. At the histochemical and the immunohistochemical levels using the usual NBF-based protocols, NBF performance was superior, followed by FineFIX/RCL2 and F-Solv. The study was published online in for the October 2011 edition of the Journal of Clinical Pathology.

Related Links:

University Medical Center Utrecht
Alphelys
Adamas




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.